NCAM1 and diffuse large B-cell lymphoma: In the last 30 years, the literature has only a few case reports or small series of CD56+ DLBCL with conflicting results on its importance.10,11,12,13,14,15,16,17,18 It could have a prognostic value; however, since new target drugs are becoming available and among them is also anti-CD56 antibody, CD56 could serve as a potential target for the treatment of patients who do not respond to standard therapeutic schemes.